This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krowchuk, D. P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Krowchuk, D. P.
Related Collections
Right arrow Dermatology

AAP Grand Rounds 3:53 (2000)
© 2000 American Academy of Pediatrics

DERMATOLOGY

Erythromycin in Pityriasis Rosea

Source: Sharma PK, Yadav TP, Gautam RK, et al. Erythromycin in pityriasis rosea: a double-blind, placebo-controlled clinical trial. J Am Acad Dermatol. 2000;42:241–244.

The first 20% of the full text of this article appears below.

The authors of this study assessed the efficacy of oral erythromycin for treating pityriasis rosea (PR). Between July 1996 and June 1998, 90 patients (65 males) with clinically diagnosed PR presenting to the dermatology outpatient department of a major hospital in New Delhi, India, were enrolled in a double-blind, placebo-controlled trial. Participants were alternately assigned to receive erythromycin stearate (250 mg q.i.d. for adults, 25–40 mg/kg/d divided q.i.d. for children) or placebo for 2 weeks. After initiating treatment, evaluations were conducted weekly for 6 weeks. . . . [Full Text of this Article]

Daniel P. Krowchuk, MD, FAAP
Pediatrics and Dermatology, Wake Forest University, Winston-Salem, NC